In this issue:
Biomarker analysis of the JAVELIN Bladder 100 trial
Body composition as a prognostic biomarker in advanced UC patients treated with ICIs
Platinum rechallenge in metastatic UC after previous PBC
Incidence and survival rates of invasive UTUC
Updated EAU risk groups for NMIBC overestimate progression risk in those treated with BCG
Novel genes associated with recurrence and progression in NMIBC
A feasibility study of preoperative pembrolizumab for high-risk UTUC
Optimal number of cycles of platinum-based first-line chemotherapy for advanced UC
Optimal number of NAC cycles in patients with MIBC
Use of NAC in patients with UTUC
Please login below to download this issue (PDF)